Takeshi Goto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
Abstract: A method for determining a position of a reference point in which there is no influence of aberration of a camera lens or the like, but an error caused by a failure in shape of an alignment mark can be reduced. An alignment mark consisting of a plurality of pattern portions (and background portions) centering at a design reference point is provided in advance. Positions of centers of border lines of the patterns are calculated. Obtained coordinate values of the centers are averaged in each axial direction. The averaged coordinate values are regarded as coordinate values of a machining reference point. Thus, even when a defect occurs in any pattern portion, an error caused by the defect is reduced so that the accuracy in machining can be improved.
Abstract: Agents potentiating nerve growth factor activity are provided for treating Alzheimer's disease which contain as the active ingredient dodecatrienoic acid derivatives represented by the general formula (I): wherein X represents hydrogen, CHO, COOH, COOR (wherein R represents an ester residue or an addition salt comprising an alkali metal salt or an organic acid salt group), provided that in case where X is COOH, it is bonded to the carbon atom at the position marked with * so as to form a lactam O?C—O—.
Abstract: A medicament for treating neurodegenerative diseases, comprising as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from the C-terminal of selenoprotein P. An excellent medicament for treating neurodegenerative diseases, especially suitable for treating neurodegenerative diseases with ataxia as a principal symptom is provided.
Abstract: A peptide fragment or a series of peptide fragments containing one or more selenocysteine that has a lowered toxicity than selenocystine and that exhibits a cytotoxicity-inhibitory activity. The peptide fragment or a series of peptide fragments according to the present invention has preferably the amino acid sequence from 260th to 362nd amino acid residues from the C-terminal of selenoprotein P, or said amino acid sequence with one or several amino acid residues therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences. A screening method for a peptide fragment having the cytotoxicity-inhibitory activity is also provided.
Abstract: A vehicle body structure for efficiently transmitting and dispersing collision energy is provided. The vehicle body structure includes a floor tunnel provided in the center of the vehicle width and extending longitudinally of a vehicle body. Side portions of the floor tunnel are joined to floor frame members provided on the right and left thereof. A rear portion of the floor tunnel is joined to center frame members provided rearward thereof. Collision energy acting on the front end of the floor tunnel is transmitted and dispersed to the right and left floor frame members and the center frame members. Collision energy acting on the floor frame members is transmitted and dispersed to the floor tunnel and the center frame members. Collision energy transmitted to the center frame memerbs is transmitted and dispersed through a plurality of crossmembers disposed rearward of the floor tunnel to the rear of the vehicle body.
Abstract: Provided in a phosphate ion adsorbent containing a weakly basic anion exchange resin as an active ingredient which aims at providing preventives and/or remedies for hyperphosphatemia having a high selectivity for the adsorption of phosphate ion and showing an effect of lowering blood phosphorus level and another effect of suppressing phosphorus excretion into the urine.
Abstract: A protective member for protecting electric wires includes: a non-woven cloth layer having flexibility and made of a chlorine-free resin; and an outer resin layer laminated monolithically on outer surface of the non-woven cloth layer, and made of a chlorine-free and fire-retardant resin, wherein a thickness of the outer resin layer is configured to be not more than a thickness of the non-woven cloth layer, and wherein a total thickness of the non-woven cloth layer and the outer resin layer is configured to have a predetermined wear resistance.
Abstract: An cross-linked anion exchange resin or a salt thereof obtained by reacting a polymer (A) having amino and/or imino groups in the total number of two or more per molecule with a compound (B) having two or more functional groups capable of reacting with amino and/or imino group contained in the polymer (A). The resin or salt has a water absorption ratio of 4.0 or lower.
Abstract: A semiconductor device manufacture method includes the steps of forming a resist layer above a work target layer; exposing and developing the resist layer to form resist patterns including isolated pattern and dense patterns; monitoring widths of isolated and dense pattern of the resist patterns to determine trimming amounts of linewidths to be reduced; determining etching conditions for realizing the trimming amounts of both the isolated and dense patterns, the etching conditions using mixed gas of a gas having a function of mainly enhancing etching and a gas having a function of mainly suppressing etching; trimming the resist pattern under said determined etching conditions; and etching the work target layer by using said trimmed resist patterns. A desired pattern width an be realized stably by trimming using plasma etching.
Abstract: Percutaneous absorption preparations for treating dementia which contain an adhesive composition, characterized in that the adhesive composition contains the active ingredient in a dispersed state, the active ingredient is released at a pharmacologically effective rate and the skin permeation rate thereof is at least 1.2 &mgr;g/cm2/h. Thus, it is possible to provide percutaneous absorption preparations whereby the therapeutic effect can be sustained over a prolonged period of time without elevating the concentration of the active ingredient in the plasma to such a level as causing the expression of side effects in the administration of remedies for dementia.
Abstract: The base sequence for the expression of a therapeutic gene and the medicament for gene therapy are disclosed. There is also disclosed the base sequence for the expression of a therapeutic gene, said sequence being shown in any one of from (a) to (d) and capable of directing the expression of the therapeutic gene specifically to squamous epithelium:
(a) the base sequence set forth in SEQ ID NO:1 in the Sequence Listing;
(b) the base sequence set forth in SEQ ID NO:18 in the Sequence Listing;
(c) the base sequence set forth in SEQ ID NO:17 in the Sequence Listing; and
(d) the base sequence set forth in SEQ ID NO:16 in the Sequence Listing.
Moreover, there is disclosed the medicament for gene therapy containing a therapeutic gene downstream any of the above-mentioned base sequences, capable of directing the expression of the therapeutic gene specifically to squamous epithelium.
Abstract: The invention provides solid preparations for oral administration of gene-related drugs comprising a core containing the gene-related drug with a coating which does not disintegrated in small intestines, wherein said preparations can be easily tabletted, remain stable during the preparation process and said drug can be efficiently absorbed in digestive tracts.
November 20, 2000
Date of Patent:
September 21, 2004
Hisamitsu Pharmaceutical, Inc.
Norifumi Tanida, Takeshi Goto, Jun Aoki
Abstract: Provide milk powders for confectionery and bakery products that, when added during the production of confectionery and bakery products, can increase the volume of breads, pancakes, cakes, pies, etc., and further add a desirable texture and feel in the mouth to breads, pancakes and cakes. Obtain milk powders for confectionery and bakery products containing 4 to 10 weight-percent of non-protein nitrogen (based on the weight of converted protein) and 1 to 20 weight-percent of ash in a manner keeping the ratio of non-protein nitrogen to total nitrogen to 0.5 or less, by intermixing, as appropriate, dairy ingredients containing non-protein nitrogen with other dairy ingredients such as whole milk powders, skim milk powders, buttermilk powders, whey powders, milk minerals, whey protein concentrates and milk protein concentrates.
Abstract: A crosslinked anion exchange resin or a salt thereof obtained by reacting a polymer (A) having amino and/or imino groups in the total number of two or more per molecule with a compound (B) having a vinyl group capable of reacting in Michael addition reaction and a carboxylic ester group, and thus by making the amino and/or imino groups contained in the polymer (A) add to the vinyl group in the compound (B) and form a amide-bond with the carboxylic ester group in the compound (B).
Abstract: There are provided immunosuppressants with few side effects that can be used to suppress rejection involving organ transplantation, and the immunosuppressants comprising antibodies against histone H1 which specifically recognize antigenic proteins may be used to suppress immunity in mammals for treatment or prevention of rejection involving organ transplantation.
Abstract: Medicinal compositions for colorectal cancer to be administered to the large intestine by taking advantage of preparations disintegrating in the large intestine, characterized by containing a cyclooxygenase inhibitor and an HMG-CoA reductase inhibitor. These compositions are appropriate for inhibiting the postoperative liver metastasis and recurrence of colorectal cancer.
Abstract: An absorption enhancer for the large intestine most suitable for an oral preparation, with a disintegration property in the large intestine, especially the absorption enhancer for the large intestine mixed with a hydrophilic medium and an absorption enhancer is provided.
Abstract: Novel medicinal compositions aiming at delivering a medicine to a specific site of the large intestine; and preparations for intestinal administration with the use of the same. Namely, medicinal compositions, whereby a medicine can be delivered to a specific site of the large intestine, characterized by containing a P-glycoprotein modifier; and preparations for intestinal administration with the use of the same.
Abstract: A novel nucleic acid carrier and a pharmaceutical composition for gene therapy are disclosed. The nucleic acid carrier of this invention is characterized by containing a polypeptide comprising diaminobutyric acid with a suitable number of residues and/or a pharmaceutically acceptable salt thereof. The nucleic acid carrier of this invention can form a complex with a variety of therapeutic genes that is safe and has extremely low immunogenicity (the pharmaceutical composition of this invention); and it can allow the therapeutic gene to be introduced into cells efficiently and safely whereby high expression of the gene in the cells can be realized.